Hyaluronidase (human recombinant)
- Generic Name
- Hyaluronidase (human recombinant)
- Brand Names
- Darzalex Faspro, Herceptin Hylecta, Hylenex, Hyqvia 5 G / 50 Ml Kit, Phesgo, Rituxan Hycela, Vyvgart Hytrulo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 757971-58-7
- Unique Ingredient Identifier
- 743QUY4VD8
- Background
A purified preparation of the enzyme recombinant human hyaluronidase. Hyaluronidase (human recombinant) (INN Vorhyaluronidase alfa) is produced by genetically engineered Chinese Hamster Ovary (CHO) cells containing a DNA plasmid encoding for a soluble fragment of human hyaluronidase (PH20). Hyaluronidase is an enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents. The action of hyaluronidase was first described in 1936, and named in 1939. Early research into hyaluronidase identified it as a "spreading factor" which allowed for increased permeability of the connective tissue. Hyaluronidase has been used in surgical settings for at least the past 60 years to improve the diffusion of local anesthetics.
Hyaluronidase was first used in prescription products in the United States on 5 May 2004.
- Indication
Hyaluronidase is indicated for subcutaneous fluid administration for hydration, and increasing resorption of radiopaque agents in subcutaneous urography. Hyaluronidase is also indicated by multiple routes to increase the dispersion of other injectable drugs.
- Associated Conditions
- Drug Extravasation, Generalized Myasthenia Gravis, Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Primary Immune Deficiency Disorders (PIDD), Primary Immunodeficiency, Secondary humoral immunodeficiency, Stage I Breast Cancer
- Associated Therapies
- Parenteral rehydration therapy, Improving resorption of radiopaque agents, To increase percutaneous drug absorption therapy
Cepheus Phase 3 Study Shows Improvement for Patients With Multiple Myeloma
DARZALEX® (daratumumab)-based maintenance regimens show clinically meaningful deep ...
Related Clinical Trials:
Johnson & Johnson's Rybrevant Scores Third FDA-Approval Of 2024 For Certain Type Of ...
Darzalex Faspro (daratumumab and hyaluronidase-fihj)-Based Quadruplet Regimen Approved in the U.S. for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.